192 related articles for article (PubMed ID: 32232903)
1. Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells.
Okimoto T; Kotani H; Iida Y; Koyanagi A; Tanino R; Tsubata Y; Isobe T; Harada M
Cancer Sci; 2020 Jun; 111(6):1910-1920. PubMed ID: 32232903
[TBL] [Abstract][Full Text] [Related]
2. High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study.
Sumiyoshi I; Okabe T; Togo S; Takagi H; Motomura H; Ochi Y; Shimada N; Haraguchi M; Shibayama R; Fujimoto Y; Watanabe J; Iwai M; Kadoya K; Iwakami SI; Takahashi K
J Transl Med; 2021 Feb; 19(1):92. PubMed ID: 33639962
[TBL] [Abstract][Full Text] [Related]
3. Pemetrexed combined with dual immune checkpoint blockade enhances cytotoxic T lymphocytes against lung cancer.
Chen MC; Hung MY; Pan CM; Huang SW; Jan CI; Li YH; Chiu SC; Cho DY
Cancer Sci; 2023 Jul; 114(7):2761-2773. PubMed ID: 37017116
[TBL] [Abstract][Full Text] [Related]
4. Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.
Okita R; Wolf D; Yasuda K; Maeda A; Yukawa T; Saisho S; Shimizu K; Yamaguchi Y; Oka M; Nakayama E; Lundqvist A; Kiessling R; Seliger B; Nakata M
PLoS One; 2015; 10(10):e0139809. PubMed ID: 26439264
[TBL] [Abstract][Full Text] [Related]
5. [pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells.
Booth L; Roberts JL; Poklepovic A; Dent P
Cancer Biol Ther; 2017 Sep; 18(9):705-714. PubMed ID: 28812434
[TBL] [Abstract][Full Text] [Related]
6. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
[TBL] [Abstract][Full Text] [Related]
7. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
Oncol Rep; 2019 Aug; 42(2):839-848. PubMed ID: 31173242
[TBL] [Abstract][Full Text] [Related]
8. 5-Fluorouracil and interleukin-2 immunochemotherapy enhances immunogenicity of non-small cell lung cancer A549 cells through upregulation of NKG2D ligands.
Zhao L; Wang WJ; Zhang JN; Zhang XY
Asian Pac J Cancer Prev; 2014; 15(9):4039-44. PubMed ID: 24935593
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed Disodium Heptahydrate Induces Apoptosis and Cell-cycle Arrest in Non-small-cell Lung Cancer Carrying an EGFR Exon 19 Deletion.
Mohiuddin M; Kasahara K
Anticancer Res; 2021 Jun; 41(6):2963-2977. PubMed ID: 34083287
[TBL] [Abstract][Full Text] [Related]
10. High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase.
Kuo WT; Tu DG; Chiu LY; Sheu GT; Wu MF
Oncol Rep; 2017 Nov; 38(5):2787-2795. PubMed ID: 28901493
[TBL] [Abstract][Full Text] [Related]
11. The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase.
Ding X; Gu Y; Jin M; Guo X; Xue S; Tan C; Huang J; Yang W; Xue M; Zhou Q; Wang W; Zhang Y
Theranostics; 2020; 10(13):6048-6060. PubMed ID: 32483437
[No Abstract] [Full Text] [Related]
12. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
[TBL] [Abstract][Full Text] [Related]
13. A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
Wehler T; Thomas M; Schumann C; Bosch-Barrera J; Viñolas Segarra N; Dickgreber NJ; Dalhoff K; Sebastian M; Corral Jaime J; Alonso M; Hynes SM; Lin J; Hurt K; Bence Lin A; Calvo E; Paz-Ares L
Lung Cancer; 2017 Jun; 108():212-216. PubMed ID: 28625637
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone alleviates pemetrexed-induced senescence in Non-Small-Cell Lung Cancer.
Ge H; Ke J; Xu N; Li H; Gong J; Li X; Song Y; Zhu H; Bai C
Food Chem Toxicol; 2018 Sep; 119():86-97. PubMed ID: 29753869
[TBL] [Abstract][Full Text] [Related]
15. Role of Sevoflurane on Natural Killer Group 2, Member D-Mediated Immune Response in Non-Small-Cell Lung Cancer: An In Vitro Study.
Jeon S; Kim HK; Kwon JY; Baek SH; Ri HS; Choi HJ; Cho HR; Lee YS; Kim JY; Kim J; Bae J; Lee HJ
Med Sci Monit; 2020 Nov; 26():e926395. PubMed ID: 33139690
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway.
Le Maux Chansac B; Missé D; Richon C; Vergnon I; Kubin M; Soria JC; Moretta A; Chouaib S; Mami-Chouaib F
Int Immunol; 2008 Jul; 20(7):801-10. PubMed ID: 18441340
[TBL] [Abstract][Full Text] [Related]
17. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures.
Della Corte CM; Barra G; Ciaramella V; Di Liello R; Vicidomini G; Zappavigna S; Luce A; Abate M; Fiorelli A; Caraglia M; Santini M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
J Exp Clin Cancer Res; 2019 Jun; 38(1):253. PubMed ID: 31196138
[TBL] [Abstract][Full Text] [Related]
19. Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer.
Al Omar SY; Marshall E; Middleton D; Christmas SE
Immunology; 2011 May; 133(1):94-104. PubMed ID: 21342183
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
